This application stems from our recent findings that i) anti-human high molecular weight-melanoma associated antigen (HMW-MAA) immunity elicited by mouse anti-id mAb MK2-23 in about 60% of patients with advanced melanoma is associated with regression of lesions in a few patients and with a statistically significant survival prolongation; ii) major histocompatibility complex plays a role in the immune response of mice to anti-id mAb MK2-23 and iii) low doses of systemic IL-2 markedly enhance the immunogenicity of mAb MK2-23 in patients with melanoma. Therefore, we plan to continue our studies to define the factors regulating the immune response to anti-id mAb MK2-23 and to enhance the immunogenicity of anti- id mAb. Specifically, we will continue to investigate the effect of the disease stage and the role of the HLA region in the development of anti- HMW-MAA immune response. The resulting information may aid to select patients who may benefit from immunotherapy with anti-id mAb. Furthermore we will explore in animal model systems approaches to enhance anti-HMW-MAA immune response by testing i) new adjuvants, ii) combinations of anti-id mAb which bear the internal image of distinct determinants of HMW-MAA and iii) fusion proteins between anti-id mAb and IL-2 and by defining the effect of antibodies to constant regions of Ig on the immunogenicity of anti-id mAb. Recurrence of melanoma in immunized patients in spite of anti-HMW-MAA immune response is likely to reflect, at least in part, low or lack of HMW-MAA expression in melanoma lesions. Therefore, this proposal aims at testing the hypothesis that the efficacy of active specific immunotherapy may be improved in patients with melanoma by combining anti-id mAb which bear the internal image of distinct determinants of HMW-MAA and of melanoma associated antigens with a non coordinate expression in melanoma lesions. To this end the immunogenicity and toxicity of the combination of anti-id mAb with this specificity will be tested in rabbits, which express both HMW-MAA and GD/3 ganglioside in their normal tissues. Rabbit immune sera will be tested for their ability to mediate immune lysis of human melanoma cells with differential expression of HMW-MAA and GD/3 ganglioside. The information resulting from studies in animal model systems will be utilized to design the immunization schedule with the most effective adjuvant and combination of anti-id mAb in patients with advanced melanoma in a phase I-II clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA051814-04A1
Application #
2094393
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1991-08-01
Project End
2000-01-31
Budget Start
1995-02-01
Budget End
1996-01-31
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
New York Medical College
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Wang, X; Luo, W; Foon, K A et al. (2001) Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. Cancer Chemother Biol Response Modif 19:309-26
Ferrone, S; Wang, X (2001) Active specific immunotherapy of malignant melanoma and peptide mimics of the human high-molecular-weight melanoma-associated antigen. Recent Results Cancer Res 158:231-5
Marincola, F M; Jaffee, E M; Hicklin, D J et al. (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
Wang, X; Luo, W; Ferrone, S (2000) Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen. Medicina (B Aires) 60 Suppl 2:48-50
Kageshita, T; Hamby, C V; Hirai, S et al. (2000) Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer 89:153-9
Kageshita, T; Hamby, C V; Hirai, S et al. (2000) Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 49:314-8
Perosa, F; Luccarelli, G; Prete, M et al. (1999) Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. Br J Haematol 106:987-94
Hicklin, D J; Marincola, F M; Ferrone, S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-86
Kageshita, T; Hirai, S; Ono, T et al. (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154:745-54
Willers, J; Lucchese, A; Kanduc, D et al. (1999) Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 20:1021-6

Showing the most recent 10 out of 42 publications